Michael Gnant

Full Professor

Medical University of Vienna

Austria

Research Interests

Explore related searches

Professors in Austria

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Michael Gnant is a Full Professor at the Medical University of Vienna, Austria. His research primarily focuses on early breast cancer management, treatment strategies for triple-negative breast cancer, and the future of surgical and clinical research. His recent publications include studies on the efficacy of CDK4/6 inhibitors and quality-of-life assessments in breast cancer trials.

Articles (10)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Collaborators (5)

Eileen Shinn

Associate Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES

View details

Marija Balic

Section chief for Medical Breast Oncology

University of Pittsburgh Medical Center

UNITED STATES

View details

Jun Mao

Chief of Integrative Medicine

Memorial Sloan Kettering Cancer Center

UNITED STATES

View details

Kwok-Leung Cheung

University of Nottingham School of Medicine

UNITED KINGDOM

View details

Jana de Boniface

Karolinska Institutet

SWEDEN

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Michael Gnant

Research Interests

Explore related searches

Contact this professor

About

Articles (10)

Treatment strategies for triple-negative primary breast cancer in older women: a systematic review

Quality-of-life and symptom severity in the PALLAS randomized trial of palbociclib with adjuvant endocrine therapy in early breast cancer (AFT-05, ABCSG-42, BIG-14-03, PrE0109)

The future of surgical research

St. Gallen/Vienna 2025 Summary of Key Messages on Therapy in Early Breast Cancer from the 2025 St. Gallen International Breast Cancer Conference

Efficacy and Safety of CDK4/6 Inhibitors: A Focus on HR+/HER2− Early Breast Cancer

Evolving treatment paradigms after CDK4/6 inhibitors in advanced breast cancer

The future of clinical trials—goals, ideas, and discussion

Assessing Knowledge, Competence, and Performance Following Web-Based Education on Early Breast Cancer Management: Health Care Professional Questionnaire Study and Anonymized Patient Records Analysis

Commentary on “Prognosis according to the timing of recurrence in breast cancer” (Ann Surg Treat Res 2023;104:1-9)

Explaining risks and benefits of loco-regional treatments to patients

Collaborators (5)

Eileen Shinn

Marija Balic

Jun Mao

Kwok-Leung Cheung

Jana de Boniface

Make your next move.